NVCT - Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024
United States
201 614 3150
https://www.nuvectis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ron Bentsur M.B.A.	Co-Founder, Chairman, CEO & Pres	851.61k	N/A	1966
Dr. Enrique Poradosu Ph.D.	Co-Founder, Exec. VP, Chief Scientific & Bus. Officer	549.07k	N/A	1967
Mr. Shay Shemesh	Co-Founder, Exec. VP, Chief Devel. & Operations Officer	529.27k	N/A	1984
Mr. Michael Carson CPA	VP of Fin.	N/A	N/A	1976

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Corporate governance

Nuvectis Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.